MCID: MSC004
MIFTS: 34

Muscle Tissue Disease malady

Categories: Muscle diseases

Aliases & Classifications for Muscle Tissue Disease

Aliases & Descriptions for Muscle Tissue Disease:

Name: Muscle Tissue Disease 12 14

Classifications:



External Ids:

Disease Ontology 12 DOID:66

Summaries for Muscle Tissue Disease

MalaCards based summary : Muscle Tissue Disease is related to distal arthrogryposis and rippling muscle disease 2. An important gene associated with Muscle Tissue Disease is DMD (Dystrophin), and among its related pathways/superpathways are DREAM Repression and Dynorphin Expression and Dilated cardiomyopathy. The drugs Dopamine and Nitric Oxide have been mentioned in the context of this disorder. Related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Muscle Tissue Disease

Diseases related to Muscle Tissue Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 77)
id Related Disease Score Top Affiliating Genes
1 distal arthrogryposis 10.5
2 rippling muscle disease 2 10.5
3 myostatin-related muscle hypertrophy 10.5
4 myotonia congenita 10.5
5 lumbar malsegmentation short stature 10.4 DMD DYSF
6 dandy-walker malformation associated with macrocephaly, facial anomalies, developmental delay, and brain stem dysgenesis 10.4 DMD UTRN
7 shigellosis 10.4 SMN1 SMN2
8 corneal dystrophy, posterior amorphous 10.4 GNE PABPN1
9 posterior polar cataract 10.4 MSTN SMN1 SMN2
10 cerebral hemorrhage 10.4 CAPN3 DYSF
11 lethal congenital contracture syndrome 5 10.4 MTM1 RYR1
12 eif2b1-related childhood ataxia with central nervous system hypomyelination/vanishing white matter 10.4 DMD SGCA
13 cardiomyopathy, familial restrictive, 3 10.4 DAG1 DMD LAMA2
14 pigmented nodular adrenocortical disease, primary, 3 10.4 MSTN SMN1 SMN2
15 sporadic hemiplegic migraine 10.4 CAPN3 FKRP
16 intrauterine growth retardation - mandibular malar hypoplasia 10.4 FKRP FKTN
17 spinal muscular atrophy-3 10.4 FKTN SMN1 SMN2
18 muscular dystrophy, rigid spine, 1 10.4 DMD DYSF LAMA2
19 adrenal cortex disease 10.3 ANO5 DYSF
20 congenital heart defects, multiple types, 3 10.3 CAPN3 DYSF FKRP
21 autosomal recessive nonsyndromic deafness 47 10.3 DAG1 DMD FKTN LAMA2
22 autosomal dominant limb-girdle muscular dystrophy type 1c 10.3 CAPN3 DYSF FKRP
23 rippling muscle disease 10.3 DYSF FKRP MSTN
24 gabrg2-related generalized epilepsy with febrile seizures plus 10.3 FKRP FKTN LAMA2
25 cardiomyopathy, dilated, 1x 10.3 DAG1 DMD FKTN LAMA2
26 neurodegeneration with brain iron accumulation 6 10.3 CAPN3 DYSF FKRP
27 osteogenesis imperfecta with opalescent teeth, blue sclerae and wormian bones but without fractures 10.3 DYSF FKRP MSTN
28 systemic epstein-barr virus-positive t-cell lymphoproliferative disease of childhood 10.3 FKRP FKTN
29 prosthetic joint infection 10.3 DMD FKRP SGCA
30 lipodystrophy, familial partial, 2 10.3 DAG1 DMD EMD LAMA2
31 malignant hyperthermia susceptibility 10.3 CAPN3 DYSF SGCA
32 nephronophthisis 2, infantile 10.3 FKRP FKTN
33 adams-oliver syndrome 2 10.3 DMD MTM1 RYR1
34 muscular dystrophy-dystroglycanopathy , type c, 1 10.3 FKRP FKTN
35 microcephaly and chorioretinopathy 2 10.3 DMD DYSF EMD RYR1
36 cone-rod dystrophy, prph2-related 10.3 DAG1 DMD FKRP FKTN
37 cubitus valgus with mental retardation and unusual facies 10.3 DMD EMD GNE LAMA2
38 charcot-marie-tooth disease, type 2b2 10.3 CAPN3 DYSF FKRP LAMA2
39 myopathy, early-onset, with fatal cardiomyopathy 10.3 CAPN3 FKRP
40 sdhc-related paraganglioma and gastric stromal sarcoma 10.3 DAG1 DMD DYSF SGCA UTRN
41 deafness, autosomal recessive 18b 10.3 ANO5 DYSF FKRP FKTN
42 premature ovarian failure 5 10.3 CLCN1 RYR1
43 asthma-related traits 6 10.3 CAPN3 DYSF FKRP SGCA
44 ullrich congenital muscular dystrophy 1 10.3 ANO5 CAPN3 DMD DYSF LAMA2
45 craniosynostosis with radiohumeral fusions and other skeletal and craniofacial anomalies 10.3 CAPN3 DYSF
46 pancreatic agenesis 1 10.3 CAPN3 DAG1 DMD DYSF SGCA
47 autosomal recessive limb-girdle muscular dystrophy type 2x 10.3 CAPN3 DYSF FKRP SGCA
48 autosomal recessive limb-girdle muscular dystrophy type 2w 10.3 CAPN3 DYSF FKRP SGCA
49 spinocerebellar ataxia 11 10.3 CAPN3 DYSF FKRP SGCA
50 lyme disease 10.3 ANO5 CAPN3 DMD DYSF GNE

Graphical network of the top 20 diseases related to Muscle Tissue Disease:



Diseases related to Muscle Tissue Disease

Symptoms & Phenotypes for Muscle Tissue Disease

MGI Mouse Phenotypes related to Muscle Tissue Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.28 CLCN1 DAG1 DMD DYSF EMD FKRP
2 homeostasis/metabolism MP:0005376 10.2 DYSF FKRP FKTN GNE LAMA2 MSTN
3 growth/size/body region MP:0005378 10.18 CAPN3 CLCN1 DAG1 DMD FKRP FKTN
4 cardiovascular system MP:0005385 10.14 CAPN3 DAG1 DMD EMD GNE MSTN
5 muscle MP:0005369 10.09 FBXO32 FKRP FKTN GNE LAMA2 MSTN
6 mortality/aging MP:0010768 10.03 CLCN1 DAG1 DMD FKRP FKTN GNE
7 no phenotypic analysis MP:0003012 9.5 CLCN1 DMD DYSF MSTN MTM1 SMN2
8 skeleton MP:0005390 9.28 CLCN1 DMD FKRP LAMA2 MSTN MTM1

Drugs & Therapeutics for Muscle Tissue Disease

Drugs for Muscle Tissue Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1161)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
2
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 10102-43-9 145068
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 50-02-2 5743
4
Mannitol Approved, Investigational Phase 4,Phase 1 69-65-8 453 6251
5
Baclofen Approved Phase 4,Phase 3,Phase 2,Phase 1 1134-47-0 2284
6
Levodopa Approved Phase 4,Phase 2,Early Phase 1 59-92-7 6047
7
Diazepam Approved, Illicit, Vet_approved Phase 4,Phase 2 439-14-5 3016
8
Bezafibrate Approved Phase 4,Phase 3,Phase 2 41859-67-0 39042
9
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 111025-46-8 4829
10
Simvastatin Approved Phase 4,Phase 2,Phase 3 79902-63-9 54454
11
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7440-66-6 32051 23994
12
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
13
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-22-0 6013
14
Paclitaxel Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 33069-62-4 36314
15
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
16
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3 51-43-4 5816
17
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 1,Phase 2 128-13-2 31401
18
Iron Approved Phase 4,Phase 2,Phase 1 7439-89-6 23925
19
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
20
Acetaminophen Approved Phase 4,Phase 2,Phase 1 103-90-2 1983
21
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
22
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
23
Valsartan Approved, Investigational Phase 4,Phase 2,Phase 1 137862-53-4 60846
24
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 1 58-93-5 3639
25
Amlodipine Approved Phase 4 88150-42-9 2162
26 Moxonidine Approved Phase 4 75438-57-2 4810
27
Donepezil Approved Phase 4,Phase 3 120014-06-4 3152
28
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-84-3 187
29
Memantine Approved, Investigational Phase 4,Phase 2 19982-08-2 4054
30
Succinylcholine Approved Phase 4,Phase 2 306-40-1 5314
31
Rocuronium Approved Phase 4,Phase 3,Phase 2,Phase 1 119302-91-9, 143558-00-3 441290
32
Alendronate Approved Phase 4,Phase 3 121268-17-5, 66376-36-1 2088
33
Propranolol Approved, Investigational Phase 4,Phase 3,Phase 2 525-66-6 4946
34
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 185243-69-0
35
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1 174722-31-7 10201696
36
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-61-7 60961
37
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
38
Naproxen Approved, Vet_approved Phase 4,Phase 1 22204-53-1 1302 156391
39
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
40
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 137-58-6 3676
41
Letrozole Approved, Investigational Phase 4,Phase 2 112809-51-5 3902
42
Amitriptyline Approved Phase 4,Phase 3,Phase 2,Phase 1 50-48-6 2160
43
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 2180-92-9, 38396-39-3 2474
44
Riluzole Approved, Investigational Phase 4,Phase 2,Phase 3 1744-22-5 5070
45
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
46 Trapidil Approved Phase 4 15421-84-8
47
Vancomycin Approved Phase 4 1404-90-6 441141 14969
48
Cortisone acetate Approved Phase 4 1950-04-4, 50-04-4 5745
49
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
50
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337

Interventional clinical trials:

(show top 50) (show all 5000)
id Name Status NCT ID Phase
1 Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype Unknown status NCT01431625 Phase 4
2 Aliskiren and Muscle Sympathetic Nerve Activity Unknown status NCT00719316 Phase 4
3 Comparison of Surgical Conditions in Cesarean Section Under General Anesthesia With Deep Neuromuscular Blockade Versus Succinylcholine Unknown status NCT01941628 Phase 4
4 The Use of Botox in Advanced Parkinson's Patients Experiencing Pain Unknown status NCT02472210 Phase 4
5 CPAP for Infantile Pompe Disease Unknown status NCT02405624 Phase 4
6 Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases Unknown status NCT01337440 Phase 4
7 The Effect of Donepezil on Gait and Balance in Parkinson's Disease Unknown status NCT01521117 Phase 4
8 Botulinum A Toxin in Patients With Parkinson's Disease Unknown status NCT00822913 Phase 4
9 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease Unknown status NCT01155128 Phase 4
10 The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Unknown status NCT01157260 Phase 4
11 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease Unknown status NCT01094769 Phase 4
12 Effect of Ranolazine on Valvular Disease in Patients With Pacemakers Unknown status NCT01979965 Phase 4
13 Influence of Profound Muscle Relaxation on Muscle Trauma and Postoperative Pulmonary Function Unknown status NCT01804933 Phase 4
14 Efficacy Study of Botox for Depression Unknown status NCT01556971 Phase 4
15 Magnesium in Liver Cirrhosis Unknown status NCT01894867 Phase 4
16 Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Generation, and Clot Strength: Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin Unknown status NCT00370045 Phase 4
17 Cyclobenzaprine Extended Release (ER) for Fibromyalgia Unknown status NCT01041495 Phase 4
18 Inspiratory Muscle Training in Patients With Autonomic Neuropathic Unknown status NCT00752440 Phase 4
19 Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace) Unknown status NCT01908556 Phase 4
20 Effects of Botulinum Toxin Type A(Meditoxin®) on Sleep Bruxism Unknown status NCT01336439 Phase 4
21 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
22 Identification of Carnitine-Responsive Cardiomyopathy Unknown status NCT01904396 Phase 4
23 Testosterone Replacement in Older Men and Atherosclerosis Progression Unknown status NCT00287586 Phase 4
24 Inspiratory Muscle Training in Patients With End Stage Renal Failure Unknown status NCT01347775 Phase 4
25 Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
26 Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy Unknown status NCT01382498 Phase 4
27 Optical Coherence Tomography (OCT) Evaluation of Re-endothelization: A Comparison of the Intrepide™ Stent Versus Taxus™ Unknown status NCT00914420 Phase 4
28 Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis Unknown status NCT00560287 Phase 4
29 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
30 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4
31 Effects of Nutritional Supplementation in Malnourished Patients in Stable COPD Unknown status NCT02197871 Phase 4
32 Botulinum Toxin in the Treatment of Idiopathic Detrusor Overactivity Unknown status NCT02009540 Phase 4
33 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Unknown status NCT00815282 Phase 4
34 Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion Unknown status NCT00313066 Phase 4
35 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4
36 Quadripolar Leads for the Management of Heart Failure Patients in the Middle East Unknown status NCT02195843 Phase 4
37 Transfusion Strategies in Weaning Patients Unknown status NCT01256645 Phase 4
38 Prevention of Posttraumatic Stress Disorder (PTSD) With Diazepam Unknown status NCT01221883 Phase 4
39 Rheumatoid Arthritis Patients in Training Unknown status NCT00434200 Phase 4
40 Hemostasis in Kocher-Langenbeck Approaches for Acetabular Surgery Using a Topical Surgical Hemostat (Vitagel) Unknown status NCT01230931 Phase 4
41 Mechanisms Underlying Postoperative Insulin Resistance and Inflammation Unknown status NCT01470534 Phase 4
42 Personalized Peroral Endoscopic Myotomy for Achalasia Unknown status NCT01570621 Phase 4
43 Thyroid Study Type 2 Diabetes Mellitus (T2DM) Unknown status NCT01379170 Phase 4
44 Botulinum Toxin A for Treatment of Catocholamine Induced Finger Necrosis Unknown status NCT01500668 Phase 4
45 Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI Unknown status NCT02298660 Phase 4
46 Inspiratory Muscle Training in Hypercapnic COPD Unknown status NCT00291460 Phase 4
47 Osteoporosis and Dental Implant Unknown status NCT00727493 Phase 4
48 Muscular Electrostimulation of the Sedated and Mechanically Ventilated Critically Ill Patient. Analysis of the Effect on Acquired Muscular Weakness and Its Clinical Consequences. Unknown status NCT02033057 Phase 4
49 Acute Effects of an Oral Fat Load on Skeletal Muscle and Hepatic Insulin Sensitivity Unknown status NCT01736202 Phase 4
50 Interaction of Statins and Nondepolarizing Muscle Relaxants Unknown status NCT02222519 Phase 4

Search NIH Clinical Center for Muscle Tissue Disease

Genetic Tests for Muscle Tissue Disease

Anatomical Context for Muscle Tissue Disease

Publications for Muscle Tissue Disease

Variations for Muscle Tissue Disease

Expression for Muscle Tissue Disease

Search GEO for disease gene expression data for Muscle Tissue Disease.

Pathways for Muscle Tissue Disease

GO Terms for Muscle Tissue Disease

Cellular components related to Muscle Tissue Disease according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 filopodium GO:0030175 9.56 DAG1 DMD MTM1 UTRN
2 Z disc GO:0030018 9.55 CAPN3 DMD FBXO32 SMN1 SMN2
3 costamere GO:0043034 9.52 DAG1 DMD
4 SMN-Sm protein complex GO:0034719 9.51 SMN1 SMN2
5 T-tubule GO:0030315 9.5 CAPN3 DYSF RYR1
6 filopodium membrane GO:0031527 9.49 DMD UTRN
7 SMN complex GO:0032797 9.46 SMN1 SMN2
8 Gemini of coiled bodies GO:0097504 9.43 SMN1 SMN2
9 contractile ring GO:0070938 9.4 DAG1 UTRN
10 dystroglycan complex GO:0016011 9.37 DAG1 SGCA
11 dystrophin-associated glycoprotein complex GO:0016010 9.35 DAG1 DMD FKRP SGCA UTRN
12 sarcolemma GO:0042383 9.23 CLCN1 DAG1 DMD DYSF FKRP LAMA2
13 cytoplasm GO:0005737 10.32 CAPN3 DAG1 DMD EMD FBXO32 GNE

Biological processes related to Muscle Tissue Disease according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 muscle contraction GO:0006936 9.7 CLCN1 DYSF EMD PABPN1 RYR1 SGCA
2 skeletal muscle tissue regeneration GO:0043403 9.62 DAG1 DMD MSTN SGCA
3 muscle cell cellular homeostasis GO:0046716 9.56 CAPN3 DMD MSTN MTM1
4 negative regulation of protein kinase B signaling GO:0051898 9.54 DAG1 MSTN MTM1
5 nuclear import GO:0051170 9.49 SMN1 SMN2
6 response to muscle activity GO:0014850 9.48 CAPN3 MSTN
7 protein O-linked mannosylation GO:0035269 9.46 FKRP FKTN
8 DNA-templated transcription, termination GO:0006353 9.43 SMN1 SMN2
9 Schwann cell differentiation GO:0014037 9.4 DAG1 LAMA2
10 response to denervation involved in regulation of muscle adaptation GO:0014894 9.35 DAG1 DMD FBXO32 SGCA UTRN
11 muscle organ development GO:0007517 9.23 CAPN3 DMD EMD FKTN LAMA2 MSTN

Molecular functions related to Muscle Tissue Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 actin binding GO:0003779 9.56 DAG1 DMD EMD UTRN
2 dystroglycan binding GO:0002162 9.16 DAG1 DMD
3 structural constituent of muscle GO:0008307 9.13 CAPN3 DAG1 DMD
4 vinculin binding GO:0017166 8.8 DAG1 DMD UTRN

Sources for Muscle Tissue Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....